<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 18 Apr 2021 13:24:53 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>​聚合行业VIC势能，助推生物医药创业创新</title><link>https://mp.weixin.qq.com/s/VvIh_elSfLwm7nGWOQfrtw</link><description></description><content:encoded><![CDATA[​聚合行业VIC势能，助推生物医药创业创新]]></content:encoded><pubDate>Sun, 18 Apr 2021 10:32:34 +0800</pubDate></item><item><title>佰傲严选：亮剑吧！您的分析仪器！</title><link>https://mp.weixin.qq.com/s/IuqhN2wmSxwjIrmTz5Xfwg</link><description></description><content:encoded><![CDATA[佰傲严选：亮剑吧！您的分析仪器！]]></content:encoded><pubDate>Sun, 18 Apr 2021 10:32:34 +0800</pubDate></item><item><title>靶点药讯56|治疗脑水肿药物获批临床、全球首款Claudin 18.2/4-1BB双特异性抗体迈入临床</title><link>https://mp.weixin.qq.com/s/UArksV9nxFFEu5YPBHHqmQ</link><description></description><content:encoded><![CDATA[靶点药讯56|治疗脑水肿药物获批临床、全球首款Claudin 18.2/4-1BB双特异性抗体迈入临床]]></content:encoded><pubDate>Sun, 18 Apr 2021 10:32:34 +0800</pubDate></item><item><title>财富密码正确？辉瑞CEO表示“可能”需要每年接种一次新冠疫苗</title><link>https://mp.weixin.qq.com/s/ciLGux2NwfkaWmHYFb78PA</link><description></description><content:encoded><![CDATA[财富密码正确？辉瑞CEO表示“可能”需要每年接种一次新冠疫苗]]></content:encoded><pubDate>Sat, 17 Apr 2021 11:19:25 +0800</pubDate></item><item><title>买家团火热来袭：你的渠道够强吗？</title><link>https://mp.weixin.qq.com/s/Of38cGoIXkN823xueWqU3A</link><description></description><content:encoded><![CDATA[买家团火热来袭：你的渠道够强吗？]]></content:encoded><pubDate>Sat, 17 Apr 2021 11:19:25 +0800</pubDate></item><item><title>2021AACR|国内药企带来双抗研究进展报告</title><link>https://mp.weixin.qq.com/s/wSYwF0fYdWuIbz1Rmc6vIw</link><description></description><content:encoded><![CDATA[2021AACR|国内药企带来双抗研究进展报告]]></content:encoded><pubDate>Sat, 17 Apr 2021 11:19:25 +0800</pubDate></item><item><title>生物制品病毒安全性控制核心策略</title><link>https://mp.weixin.qq.com/s/-6QLzvnNLxyy3uYEoBQq9g</link><description></description><content:encoded><![CDATA[生物制品病毒安全性控制核心策略]]></content:encoded><pubDate>Fri, 16 Apr 2021 11:56:36 +0800</pubDate></item><item><title>2021 AACR|阿诺医药公布anti-hTNFR2（AN3025）抗体临床前数据</title><link>https://mp.weixin.qq.com/s/mzU4up1iISdmuv2XOLG58A</link><description></description><content:encoded><![CDATA[2021 AACR|阿诺医药公布anti-hTNFR2（AN3025）抗体临床前数据]]></content:encoded><pubDate>Fri, 16 Apr 2021 11:56:36 +0800</pubDate></item><item><title>百亿大品种，渤健多发性硬化药物“富马酸二甲酯”获NMPA批准上市</title><link>https://mp.weixin.qq.com/s/8Jqk8F6cLc03OB_m7cOylg</link><description></description><content:encoded><![CDATA[百亿大品种，渤健多发性硬化药物“富马酸二甲酯”获NMPA批准上市]]></content:encoded><pubDate>Fri, 16 Apr 2021 11:56:36 +0800</pubDate></item><item><title>双特异性抗体：on-target off-tumor毒性及克服策略</title><link>https://mp.weixin.qq.com/s/QfQbQgrCOVe4Ag0P4iXhRw</link><description></description><content:encoded><![CDATA[双特异性抗体：on-target off-tumor毒性及克服策略]]></content:encoded><pubDate>Fri, 16 Apr 2021 11:56:36 +0800</pubDate></item><item><title>药企福利·免费注册进行时！国内首个聚焦生物药质量领域的千人大会！</title><link>https://mp.weixin.qq.com/s/UyuZe-3-e1XVir_UkBHmGw</link><description></description><content:encoded><![CDATA[药企福利·免费注册进行时！国内首个聚焦生物药质量领域的千人大会！]]></content:encoded><pubDate>Fri, 16 Apr 2021 11:56:36 +0800</pubDate></item><item><title>如何解决细胞数量和活率分析的可靠性和一致性烦恼？</title><link>https://mp.weixin.qq.com/s/VYpJgyeXoB099JfN60LXMg</link><description></description><content:encoded><![CDATA[如何解决细胞数量和活率分析的可靠性和一致性烦恼？]]></content:encoded><pubDate>Thu, 15 Apr 2021 12:20:29 +0800</pubDate></item><item><title>2021 AACR|获批尿路上皮癌适应证后，君实PD-1单抗多项新辅助疗法再亮相</title><link>https://mp.weixin.qq.com/s/c7ECEDcwr_Ppo8Z6uJ0EWw</link><description></description><content:encoded><![CDATA[2021 AACR|获批尿路上皮癌适应证后，君实PD-1单抗多项新辅助疗法再亮相]]></content:encoded><pubDate>Thu, 15 Apr 2021 12:20:29 +0800</pubDate></item><item><title>2021 AACR|蓝鸟报告溶瘤病毒可增强CAR-T疗法抗实体瘤疗效</title><link>https://mp.weixin.qq.com/s/oDDkOqF78-RDqcJW732-pg</link><description></description><content:encoded><![CDATA[2021 AACR|蓝鸟报告溶瘤病毒可增强CAR-T疗法抗实体瘤疗效]]></content:encoded><pubDate>Thu, 15 Apr 2021 12:20:29 +0800</pubDate></item><item><title>重磅！Thermo Fisher超150亿美元收购CRO公司PPD</title><link>https://mp.weixin.qq.com/s/54-2znLIQyeViy4_OBmRMQ</link><description></description><content:encoded><![CDATA[重磅！Thermo Fisher超150亿美元收购CRO公司PPD]]></content:encoded><pubDate>Thu, 15 Apr 2021 12:20:29 +0800</pubDate></item><item><title>7.64亿元，市场监管总局依法对扬子江药业集团有限公司实施垄断协议行为作出行政处罚</title><link>https://mp.weixin.qq.com/s/mTgYwsqfxhi8VFMTbOQkoA</link><description></description><content:encoded><![CDATA[7.64亿元，市场监管总局依法对扬子江药业集团有限公司实施垄断协议行为作出行政处罚]]></content:encoded><pubDate>Thu, 15 Apr 2021 12:20:29 +0800</pubDate></item><item><title>20位前FDA/NMPA审评专家将联袂上演新药中美欧多报大片</title><link>https://mp.weixin.qq.com/s/SHFt1MvjvFLofxnQYz9eRg</link><description></description><content:encoded><![CDATA[20位前FDA/NMPA审评专家将联袂上演新药中美欧多报大片]]></content:encoded><pubDate>Thu, 15 Apr 2021 12:20:29 +0800</pubDate></item><item><title>专访丨艺妙神州联合创始人&amp;CTO齐菲菲： 百舟竞流，何以争锋？—CAR-T新锐的成长解读</title><link>https://mp.weixin.qq.com/s/rNzsrdzroB86_mCIH3V-Ug</link><description></description><content:encoded><![CDATA[专访丨艺妙神州联合创始人&CTO齐菲菲： 百舟竞流，何以争锋？—CAR-T新锐的成长解读]]></content:encoded><pubDate>Wed, 14 Apr 2021 12:06:15 +0800</pubDate></item><item><title>今日直播 | 逆流而上的抗改</title><link>https://mp.weixin.qq.com/s/KMtMn_MAGNNXj073snSXXw</link><description></description><content:encoded><![CDATA[今日直播 | 逆流而上的抗改]]></content:encoded><pubDate>Wed, 14 Apr 2021 12:06:15 +0800</pubDate></item><item><title>再爆&#34;罕见血栓&#34;，CDC和FDA呼吁暂停接种强生新冠腺病毒载体疫苗</title><link>https://mp.weixin.qq.com/s/DC6g3u_cya08nAQRK5QjJA</link><description></description><content:encoded><![CDATA[再爆"罕见血栓"，CDC和FDA呼吁暂停接种强生新冠腺病毒载体疫苗]]></content:encoded><pubDate>Wed, 14 Apr 2021 12:06:15 +0800</pubDate></item></channel></rss>